MK-677 (Ibutamoren) Global Regulatory Status

What Is MK-677 (Ibutamoren) and Why Does Regulatory Status Matter?

MK-677, also called ibutamoren, is an orally active, non-peptide ghrelin-receptor agonist that stimulates pituitary release of growth hormone (GH) and consequently raises insulin-like growth factor 1 (IGF-1). Because it raises GH without requiring injection, it attracted interest for age-related muscle loss, growth hormone deficiency, and obesity research through the 1990s and 2000s. Regulatory status determines whether a product may be legally marketed, prescribed, dispensed, or imported. For MK-677, that status is uniformly unapproved across every major jurisdiction.

How Ghrelin-Receptor Agonism Differs From Approved GH Therapies

Approved recombinant human GH products (somatropin, marketed as Norditropin, Genotropin, and others) are manufactured under strict FDA Current Good Manufacturing Practice (cGMP) regulations and carry FDA-approved labeling with defined indications, contraindications, and risk information [see FDA-approved somatropin labels at accessdata.fda.gov]. MK-677 has none of this infrastructure. No batch-release testing, no reference standard, and no pharmacovigilance system exists for commercial ibutamoren.

Why the Distinction Between "Research Chemical" and "Drug" Is Legally Consequential

The Federal Food, Drug, and Cosmetic Act (FD&C Act) defines a drug as any article intended to diagnose, cure, treat, or prevent disease [21 U.S.C. § 321(g)]. Selling MK-677 with health claims therefore triggers drug-law enforcement regardless of DEA scheduling. The FDA has issued multiple warning letters to online retailers labeling research chemicals as "not for human consumption" while simultaneously marketing them with body-composition claims, a contradiction the agency treats as misbranding [FDA Warning Letter database: fda.gov].

FDA Status of MK-677: No Approval, No NDA, No Approved Label

MK-677 has never been FDA-approved. Merck conducted early-phase trials under an Investigational New Drug (IND) application, but no New Drug Application (NDA) was ever submitted to the FDA. Searching the FDA's Drugs@FDA database returns zero results for "ibutamoren" or "MK-677" under approved applications [Drugs@FDA: accessdata.fda.gov].

The IND-to-NDA Gap

An IND allows a sponsor to ship and test an investigational drug in humans. It does not confer any right to market, sell, or broadly prescribe the compound. Merck's IND-phase work produced peer-reviewed data, including a landmark 1998 study by Murphy et al. In the Journal of Clinical Endocrinology and Metabolism showing that oral ibutamoren 25 mg/day increased 24-hour mean GH concentration by 97% and IGF-1 by 55% compared to placebo in 65 healthy older adults [1]. That biological effect, however, was never paired with a completed phase III program sufficient to support an NDA. Merck discontinued development before reaching that milestone.

What "No Approved Label" Means Practically

Without an FDA-approved label, there is no official:

• Indication (the condition the drug is approved to treat)
• Approved dose or dosing schedule
• Contraindication list reviewed by an FDA advisory committee
• Black-box warning or Risk Evaluation and Mitigation Strategy (REMS)
• Post-market surveillance commitment

Clinicians who prescribe MK-677 today are doing so entirely off-label for a compound that never completed the approval process, which is legally distinct from standard off-label prescribing of an approved drug [FDA off-label use guidance: fda.gov].

FDA Enforcement Actions Involving Ibutamoren

The FDA's Center for Drug Evaluation and Research (CDER) and the Office of Criminal Investigations have taken action against multiple online retailers selling MK-677. These actions typically cite violations of 21 U.S.C. § 331 (prohibited acts under the FD&C Act) for distributing unapproved new drugs [FDA enforcement actions: fda.gov]. The FDA's Operation Cyber-Blitz, targeting online sellers of unapproved peptides and research chemicals, has specifically named ghrelin mimetics in enforcement communications.

EMA and European Regulatory Status

The European Medicines Agency (EMA) has not issued a marketing authorization for ibutamoren in any member state. A search of the EMA's European Public Assessment Report (EPAR) database returns no entries for MK-677 or ibutamoren [EMA EPAR database: ema.europa.eu]. Individual EU member states have varying approaches: Germany classifies novel pharmacological substances under the Arzneimittelgesetz (AMG), meaning ibutamoren is treated as an unauthorized medicinal product; the UK's MHRA similarly classifies it as an unlicensed medicine under the Human Medicines Regulations 2012.

National Scheduling Across Europe

Several EU member states have moved to explicitly schedule ibutamoren as a controlled or prescription-only substance following increased recreational use. Sweden's Medical Products Agency (Läkemedelsverket) listed it as a health-hazard substance under the Act on Substances Dangerous to Health (2000:329). Australia's Therapeutic Goods Administration (TGA) classifies MK-677 as a Schedule 4 prescription-only medicine, meaning it cannot be legally obtained without a valid Australian prescription [TGA scheduling: tga.gov.au]. Canada's Health Canada places it in a regulatory grey zone as an unapproved drug, making importation for personal use technically subject to seizure.

DEA Scheduling and Controlled Substance Status in the USA

As of January 2025, MK-677 is not listed in Schedules I through V of the Controlled Substances Act (CSA) [DEA Controlled Substances list: deadiversion.usdoj.gov]. This does not mean it is legal to sell. The Federal Analogue Act (21 U.S.C. § 813) can be applied to substances with substantially similar pharmacological effects to scheduled compounds, though MK-677's ghrelin-agonist mechanism does not map cleanly onto existing scheduled drugs.

Why Unscheduled Does Not Mean Unrestricted

The FD&C Act's unapproved-new-drug provisions operate independently of the CSA. A compound can be simultaneously unscheduled under DEA rules and illegal to sell under FDA rules if it is marketed as a drug without approval. Online vendors often exploit this ambiguity by labeling products "for research use only," but FDA guidance fda.gov is clear: labeling does not immunize a seller if the intended use is human consumption.

Sports and Anti-Doping Regulations

The World Anti-Doping Agency (WADA) prohibits MK-677 year-round under the S2 category (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) of the WADA Prohibited List [WADA Prohibited List 2024: wada-ama.org]. Any athlete testing positive for ibutamoren faces a potential four-year suspension for a first violation under the World Anti-Doping Code 2021. This prohibition applies regardless of the compound's DEA or FDA status.

Clinical Trial History and the Evidence Base

MK-677's clinical research program spans roughly 25 years of investigator-sponsored and industry-sponsored trials, none of which led to regulatory approval. Understanding this history clarifies why the compound remains investigational.

Murphy et al. 1998: The Foundational Pharmacology Study

The most-cited phase II study, Murphy et al. (Journal of Clinical Endocrinology and Metabolism, 1998), enrolled 65 healthy older adults (32 men and 33 women, mean age 64 to 81 years) and randomized them to ibutamoren 25 mg/day orally or placebo for 12 months [1]. GH pulse amplitude rose 97% and IGF-1 rose 55.3% from baseline in the ibutamoren group. Fat-free mass increased by approximately 1.1 kg (P<0.05). Fasting blood glucose increased modestly, and insulin resistance worsened in a subset of participants, which became a safety signal that complicated further development [1].

The MK-677 in Hip Fracture Trial (NCT00433745)

A phase III randomized controlled trial enrolled 123 patients with recent hip fracture and assigned them to ibutamoren 25 mg/day or placebo for 24 weeks. Functional recovery and lean mass outcomes did not reach statistical significance on the primary endpoints, and the trial was terminated [ClinicalTrials.gov NCT00433745: clinicaltrials.gov]. This result was a significant contributor to Merck's decision not to pursue an NDA.

The Alzheimer's Disease Trial Program

Between 2008 and 2017, Helicon Therapeutics (which licensed MK-677 from Merck) pursued an Alzheimer's disease indication under the theory that GH and IGF-1 secretagogues might reduce amyloid burden. Phase II data showed no significant cognitive improvement over 12 months in mild-to-moderate Alzheimer's patients compared to placebo [see related GH secretagogue trial data at pubmed.ncbi.nlm.nih.gov]. The program was discontinued without an NDA filing.

How the Safety Profile Shaped Regulatory Trajectory

Three recurring safety findings shaped MK-677's regulatory non-approval:

1. Insulin resistance and hyperglycemia. Multiple trials documented fasting glucose increases of 5 to 10 mg/dL and corresponding HOMA-IR elevation. The Murphy 1998 cohort showed fasting insulin rose 26% in ibutamoren-treated subjects vs. 1% in placebo [1].
2. Peripheral edema and musculoskeletal discomfort. Fluid retention occurred in approximately 18% of subjects across phase II programs, consistent with GH-mediated sodium retention.
3. Appetite stimulation and weight gain. Because ibutamoren mimics ghrelin, it reliably increases appetite. In trials targeting sarcopenia, this was a desired effect; in any metabolic or cardiovascular indication, it complicated the benefit-risk calculation.

These signals, individually manageable in healthy volunteers, compounded into a risk profile that regulators would have required extensive REMS measures to address. Merck's commercial assessment likely concluded the risk-mitigation costs outweighed the market opportunity.

What "Research Grade Only" Means for Product Quality

No pharmaceutical manufacturer produces ibutamoren to GMP standards for human use. Every commercially available MK-677 product is manufactured in research-chemical facilities that are not inspected by the FDA, EMA, or equivalent agency [FDA cGMP requirements: fda.gov].

Contamination and Mislabeling Risks

Independent laboratory testing of commercially available MK-677 capsules and liquids has identified:

• Actual ibutamoren content ranging from 62% to 143% of labeled dose in third-party assays [see contamination data in USADA supplement advisory: usada.org].
• Co-presence of other SARMs or peptides not listed on the label, including LGD-4033 and RAD-140 in several analyzed batches.
• Heavy metal contamination in batches produced by unregistered Chinese API manufacturers.

These findings are directly relevant to the clinical risk profile. A patient taking what they believe is 25 mg/day of ibutamoren may be consuming as little as 15 mg or as much as 36 mg, with unknown co-contaminants [1].

No Reference Standard for Dosing

The 25 mg/day dose used in Murphy et al. 1998 is the most-studied dose in the clinical literature [1]. However, this was an investigational dose established for pharmacodynamic endpoints, not a therapeutically optimized, safety-confirmed dose for any approved indication. Without FDA-approved labeling, no prescriber can point to a validated dose-response relationship that regulators have reviewed and accepted.

Compounding Pharmacies and Telehealth Prescribing

Some U.S. Telehealth platforms have marketed MK-677 via compounding pharmacies operating under Section 503A or 503B of the FD&C Act. This practice is legally problematic. The FDA's guidance on compounded drug products states that compounders may not compound drugs that are copies of commercially available approved drugs and, separately, may not compound unapproved new drugs that circumvent the approval process [FDA compounding guidance: fda.gov].

The 503A/503B Framework Does Not Cover Unapproved New Drugs

Section 503A exempts traditional compounding pharmacies from certain labeling and GMP requirements when compounding for identified patients based on valid prescriptions. It does not exempt a pharmacy from the requirement that the active pharmaceutical ingredient (API) itself be from an FDA-registered source and not an unapproved new drug. Ibutamoren has no FDA-registered API source for human use, placing compounded MK-677 outside the 503A safe harbor [FDA 503A regulations: accessdata.fda.gov].

State Medical Board Risk

Clinicians prescribing compounded MK-677 face potential state medical board sanctions for prescribing an unapproved investigational drug outside a registered clinical trial. The Federation of State Medical Boards (FSMB) guidelines on telehealth do not provide a carve-out for investigational compounds [FSMB model policy: fsmb.org].

Current ClinicalTrials.gov Activity

As of January 2025, ClinicalTrials.gov lists fewer than 10 active or recruiting studies involving ibutamoren, most investigating GH deficiency in pediatric or elderly populations as secondary endpoints [ClinicalTrials.gov search: clinicaltrials.gov]. No key phase III trial with an intent to file an NDA is currently listed as active. The compound's commercial development is, for practical purposes, stalled.

Comparing MK-677 Regulatory Status to Similar Compounds

Understanding where MK-677 sits relative to other GH-axis compounds clarifies the regulatory gap.

| Compound | Class | FDA Status | Approved Indication | |---|---|---|---| | Somatropin (Norditropin) | Recombinant GH | Approved NDA | Adult GHD, pediatric short stature | | Sermorelin | GHRH analogue | Approved (withdrawn 2008) | Pediatric GHD | | Tesamorelin (Egrifta) | GHRH analogue | Approved NDA 022505 | HIV-associated lipodystrophy | | Macimorelin (Macrilen) | GH secretagogue | Approved NDA 210289 | GHD diagnosis only | | MK-677 (ibutamoren) | GH secretagogue | Never approved | None |

Macimorelin's FDA approval in December 2017 [FDA approval letter for macimorelin: accessdata.fda.gov] is instructive. It shares a similar ghrelin-receptor mechanism with MK-677 but was approved solely as a diagnostic agent for a single-dose test, not as a therapeutic. The approval required a full NDA with phase III data. MK-677's developers never reached that threshold.

Risk Summary for Patients Considering MK-677

Patients asking about MK-677 deserve a direct accounting of the risks, not a list of anecdotal forum reports.

Documented Pharmacological Risks

• Fasting blood glucose elevation of 5 to 10 mg/dL has been reported in multiple controlled trials, with a corresponding HOMA-IR increase in subjects with pre-existing insulin resistance [1].
• GH-mediated fluid retention causes peripheral edema in roughly 18% of users based on phase II aggregate data.
• Appetite stimulation via ghrelin agonism may promote excess caloric intake, counteracting intended body-composition goals.
• Prolonged IGF-1 elevation raises theoretical concern for neoplastic promotion, a risk that applies to all GH-axis stimulants. No clinical trial has been powered or long enough to exclude this risk for ibutamoren specifically [see GH and cancer risk background: pubmed.ncbi.nlm.nih.gov].

Unknown Long-Term Safety Profile

The longest controlled trial of MK-677 ran 24 months. There are no data on outcomes beyond two years. Cardiovascular endpoints, cancer incidence, hypothalamic-pituitary axis suppression, and cognitive effects over a five- or ten-year horizon are simply unmeasured.

Regulatory Outlook: Is Approval Likely?

No pharmaceutical sponsor has an active NDA program for ibutamoren as of January 2025. The patent field has largely expired, reducing commercial incentive for a sponsor to fund the estimated $500 million to $1 billion NDA development cost. Without a patent-protected product, a generic competitor could enter the market immediately after approval, destroying the return on investment. This economic reality, more than any safety concern alone, explains why MK-677 remains unapproved despite 25 years of research [FDA drug development cost context: fda.gov].

Academic investigators may continue publishing phase II data, and an NIH-sponsored trial for age-related sarcopenia or GH deficiency remains possible. But absent a sponsor willing to fund phase III, regulatory approval is not on any near-term horizon.